Skip to content

Study · Randomized controlled trial · n = 43 · 2009

8 results

Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer.

Dockery F, Bulpitt CJ, Agarwal S, Vernon C, Rajkumar C

Journal of andrology22 Jan 2009Cited by 23 (Europe PMC)

PMID19168445 (opens in a new tab)DOI10.2164/jandrol.108.006924 (opens in a new tab)PepBankPUB-19168445
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In men with prostate cancer, radial pulse wave velocity changes were not significantly different between goserelin and bicalutamide at 12 weeks (P >or= .967).

    In plain wordsIn men with prostate cancer, radial artery stiffness changes were not significantly different between goserelin and bicalutamide at 12 weeks.

    Peptide
    Goserelin
    Outcome
    No significant changeRadial pulse wave velocity change at 12 weeks
    Study

    n = 43

    Comparator
    Bicalutamide
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    P value
    ≥ 0.967 unitless
    radial PWV change, goserelin vs bicalutamide, 12 weeks

    Source sentences

    Summary
    however, comparison of changes between the 2 drugs were not significantly different at either 12 or 24 weeks (P >or= .967 at 12 weeks and P >or= .07 at 24 weeks).
    2 context sentences
    Summary · context
    We conducted a randomized trial on 43 men (mean age, 71.2 +/- 6.2 years) with localized prostate cancer.
    Summary · context
    They received either goserelin or bicalutamide for 24 weeks.
  2. 02HumanRandomized controlled trialSafety outcome

    In men with prostate cancer, femoral pulse wave velocity changes were not significantly different between goserelin and bicalutamide at 12 weeks (P >or= .967).

    In plain wordsIn men with prostate cancer, femoral artery stiffness changes were not significantly different between goserelin and bicalutamide at 12 weeks.

    Peptide
    Goserelin
    Outcome
    No significant changeFemoral pulse wave velocity change at 12 weeks
    Study

    n = 43

    Comparator
    Bicalutamide
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    P value
    ≥ 0.967 unitless
    femoral PWV change, goserelin vs bicalutamide, 12 weeks

    Source sentences

    Summary
    however, comparison of changes between the 2 drugs were not significantly different at either 12 or 24 weeks (P >or= .967 at 12 weeks and P >or= .07 at 24 weeks).
    2 context sentences
    Summary · context
    We conducted a randomized trial on 43 men (mean age, 71.2 +/- 6.2 years) with localized prostate cancer.
    Summary · context
    They received either goserelin or bicalutamide for 24 weeks.
  3. 03HumanRandomized controlled trialSafety outcome

    In men with prostate cancer, radial pulse wave velocity changes were not significantly different between goserelin and bicalutamide at 24 weeks (P >or= .07).

    In plain wordsIn men with prostate cancer, radial artery stiffness changes were not significantly different between goserelin and bicalutamide at 24 weeks.

    Peptide
    Goserelin
    Outcome
    No significant changeRadial pulse wave velocity change at 24 weeks
    Study

    n = 43

    Comparator
    Bicalutamide
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    P value
    ≥ 0.07 unitless
    radial PWV change, goserelin vs bicalutamide, 24 weeks

    Source sentences

    Summary
    however, comparison of changes between the 2 drugs were not significantly different at either 12 or 24 weeks (P >or= .967 at 12 weeks and P >or= .07 at 24 weeks).
    2 context sentences
    Summary · context
    We conducted a randomized trial on 43 men (mean age, 71.2 +/- 6.2 years) with localized prostate cancer.
    Summary · context
    They received either goserelin or bicalutamide for 24 weeks.
  4. 04HumanRandomized controlled trialSafety outcome

    In men with prostate cancer, femoral pulse wave velocity changes were not significantly different between goserelin and bicalutamide at 24 weeks (P >or= .07).

    In plain wordsIn men with prostate cancer, femoral artery stiffness changes were not significantly different between goserelin and bicalutamide at 24 weeks.

    Peptide
    Goserelin
    Outcome
    No significant changeFemoral pulse wave velocity change at 24 weeks
    Study

    n = 43

    Comparator
    Bicalutamide
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    P value
    ≥ 0.07 unitless
    femoral PWV change, goserelin vs bicalutamide, 24 weeks

    Source sentences

    Summary
    however, comparison of changes between the 2 drugs were not significantly different at either 12 or 24 weeks (P >or= .967 at 12 weeks and P >or= .07 at 24 weeks).
    2 context sentences
    Summary · context
    We conducted a randomized trial on 43 men (mean age, 71.2 +/- 6.2 years) with localized prostate cancer.
    Summary · context
    They received either goserelin or bicalutamide for 24 weeks.
  5. 05HumanNon-randomized trialSafety outcome

    In men with prostate cancer, goserelin increased radial pulse wave velocity by 1.4 m/s from baseline at 12 weeks (P = .002).

    In plain wordsIn men with prostate cancer, radial artery stiffness increased from baseline after 12 weeks of goserelin.

    Peptide
    Goserelin
    Outcome
    IncreaseRadial pulse wave velocity at 12 weeks
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Change in radial artery PWV from baseline
    1.4 m/s
    goserelin, 12 weeks
    P value
    0.002 unitless
    radial PWV change from baseline, goserelin, 12 weeks

    Source sentences

    Summary
    After 12 weeks of goserelin, radial artery PWV increased significantly from baseline and a nonsignificant increase was observed in femoral PWV (change from baseline radial: +1.4 m/s, P = .002, femoral: +0.9 m/s, P = .127)
    2 context sentences
    Summary · context
    We conducted a randomized trial on 43 men (mean age, 71.2 +/- 6.2 years) with localized prostate cancer.
    Summary · context
    They received either goserelin or bicalutamide for 24 weeks.
  6. 06HumanNon-randomized trialSafety outcome

    In men with prostate cancer, femoral pulse wave velocity increased nonsignificantly by 0.9 m/s after 12 weeks of goserelin (P = .127).

    In plain wordsIn men with prostate cancer, femoral artery stiffness did not increase significantly from baseline after 12 weeks of goserelin.

    Peptide
    Goserelin
    Outcome
    No significant changeFemoral pulse wave velocity at 12 weeks
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Change in femoral PWV from baseline
    0.9 m/s
    goserelin, 12 weeks
    P value
    0.127 unitless
    femoral PWV change from baseline, goserelin, 12 weeks

    Source sentences

    Summary
    After 12 weeks of goserelin, radial artery PWV increased significantly from baseline and a nonsignificant increase was observed in femoral PWV (change from baseline radial: +1.4 m/s, P = .002, femoral: +0.9 m/s, P = .127)
    2 context sentences
    Summary · context
    We conducted a randomized trial on 43 men (mean age, 71.2 +/- 6.2 years) with localized prostate cancer.
    Summary · context
    They received either goserelin or bicalutamide for 24 weeks.
  7. 07HumanNon-randomized trialSafety outcome

    In men with prostate cancer, goserelin increased radial pulse wave velocity by 1.7 m/s from baseline at 24 weeks (P <or= .049).

    In plain wordsIn men with prostate cancer, radial artery stiffness increased from baseline after 24 weeks of goserelin.

    Peptide
    Goserelin
    Outcome
    IncreaseRadial pulse wave velocity at 24 weeks
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Change in radial artery PWV from baseline
    1.7 m/s
    goserelin, 24 weeks
    P value
    ≤ 0.049 unitless
    PWV change from baseline, goserelin, 24 weeks (radial and femoral)

    Source sentences

    Summary
    PWV increased further after 24 weeks with goserelin (change from baseline radial: +1.7, femoral: +1.3 m/s, P <or= .049 for both)
    2 context sentences
    Summary · context
    We conducted a randomized trial on 43 men (mean age, 71.2 +/- 6.2 years) with localized prostate cancer.
    Summary · context
    They received either goserelin or bicalutamide for 24 weeks.
  8. 08HumanNon-randomized trialSafety outcome

    In men with prostate cancer, goserelin increased femoral pulse wave velocity by 1.3 m/s from baseline at 24 weeks (P <or= .049).

    In plain wordsIn men with prostate cancer, femoral artery stiffness increased from baseline after 24 weeks of goserelin.

    Peptide
    Goserelin
    Outcome
    IncreaseFemoral pulse wave velocity at 24 weeks
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Change in femoral PWV from baseline
    1.3 m/s
    goserelin, 24 weeks
    P value
    ≤ 0.049 unitless
    PWV change from baseline, goserelin, 24 weeks (radial and femoral)

    Source sentences

    Summary
    PWV increased further after 24 weeks with goserelin (change from baseline radial: +1.7, femoral: +1.3 m/s, P <or= .049 for both)
    2 context sentences
    Summary · context
    We conducted a randomized trial on 43 men (mean age, 71.2 +/- 6.2 years) with localized prostate cancer.
    Summary · context
    They received either goserelin or bicalutamide for 24 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.